Blog Posts - Januvia



New FDA Warning That Januvia, Onglyza, Tradjenta, And Nesina Are Associated With "joint pain that can be severe and disabling"

Label Changes About Side Effects For These Type 2 Diabetes Medicines In The Drug Class Called Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Posted by Tom Lamb at DrugInjuryWatch.com) In August 2015 the FDA announced that it has found indications of a ne...
by Drug Injury Watch on Aug 28, 2015

Pancreatic Cancer As A Side Effect Of Diabetes Drugs Bydureon, Byetta, Januvia, And Victoza

Health Canada Currently Conducting Epidemiological Study Of These Incretin-Based Type 2 Diabetes Medications To Assess This Potential Drug Safety Issue (Posted by Tom Lamb at DrugInjuryWatch.com) From the October 2014 edition of the Canadian Adverse...
by Drug Injury Watch on Jan 19, 2015

Byetta And Januvia: More Debate About The Possible Increased Risk Of Pancreatitis, Pancreatic Cancer, And Thyroid Cancer

Level Of Concern About These Incretin Therapies For Diabetes Was Raised By Gastroenterology Medical Journal Article (Posted by Tom Lamb at DrugInjuryWatch.com) In September 2011, at the 47th European Association for the Study of Diabetes (EASD) Annua...
by Drug Injury Watch on Nov 17, 2011

Acute Pancreatitis Case Associated With Victoza Use, Similar To Byetta And Januvia Case Reports

Drug Safety Issue Controversy Continues: True Serious Side Effect, Or Attributable To Type 2 Diabetes Condition (Posted by Tom Lamb at DrugInjuryWatch.com) Novo Nordisk has a relatively new diabetes drug, Victoza (liraglutide), approved by FDA in 201...
by Drug Injury Watch on Jun 6, 2011

Medical Journal Withdraws Article About Januvia And Byetta After It Gets Letters From Two Drug Companies

April 2011 Edition Of BMJ Breaks News And Provides Insight From One Who Saw An Increased Risk Of Pancreatitis (Posted by Tom Lamb at DrugInjuryWatch.com) According to a news item published April 11, 2011 by The British Medical Journal (BMJ), letters...
by Drug Injury Watch on May 2, 2011

Case Report: Man Using Diabetes Medication Januvia Develops Elevated Hepatic Enzymes

Authors Suggest That Certain Patients Starting Januvia Should Have Their Liver Function Monitored (Posted by Tom Lamb at DrugInjuryWatch.com) In the recent past we considered whether Januvia (sitagliptin) can cause pancreatitis in patients using this...
by Drug Injury Watch on Feb 8, 2010

A Review Of Recent Research On Issue Of Whether Januvia Can Cause Pancreatitis

Is Pancreatitis A Januvia Side Effect Or Is There An Increased Risk Of This Medical Condition Among Type 2 Diabetics Across All Treatments (Posted by Tom Lamb at DrugInjuryWatch.com) A few weeks back we reported that the FDA wants Merck to change the...
by Drug Injury Watch on Oct 12, 2009

FDA Wants Merck To Change Januvia Label With Increased Warning About Pancreatitis Risk

Is Januvia Similar To Byetta In Terms Of The So-Called Class Effect And Drug Injury Lawsuits Being Filed? (Posted by Tom Lamb at DrugInjuryWatch.com) On September 25, 2009 the FDA posted on its web site "Information for Healthcare Professionals...
by Drug Injury Watch on Sep 29, 2009

FDA Wants Merck To Change Januvia Label With Increased Warning About Pancreatitis Risk

Is Januvia Similar To Byetta In Terms Of The So-Called Class Effect And Drug Injury Lawsuits Being Filed? (Posted by Tom Lamb at DrugInjuryWatch.com) On September 25, 2009 the FDA posted on its web site "Information for Healthcare Professionals...
by Drug Injury Watch on Sep 29, 2009

MERCK arm to sell cheap ANTIDIABETES DRUG

MSD Pharmaceuticals, subsidiary of over $24 billion Merck Inc, launched its blocki-buster diabetes drug, JANUVIA (sitagliptin) in India at one-fifth the US price. This is perhaps one of the few instances where a drug is cheaper in India, as against i...
by MONEY FOR PHARMACISTS on Sep 22, 2009

FDA approves Onglyza (saxagliptin)

FDA approved Onglyza (saxagliptin) for type 2 diabetes. This is the 2nd DPP-IV inhibitor to be approved. The first DPP-IV was Januvia (sitagliptin).Here's the FDA press release:The U.S. Food and Drug Administration today approved Onglyza (saxagliptin...

ADA 2009: New Drugs for Type 2 Diabetes

Much has changed in the world of type 2 diabetes. In the past, we used to write type 2 diabetes as type II diabetes (notice the difference between 2 vs. II)? At ADA this year, we're seeing some exciting research about new treatment options for type 2...

Study Shows Weekly Byetta Diabetes Drug Outdoes Competitors - Wall Street Journal

Study Shows Weekly Byetta Diabetes Drug Outdoes Competitors Wall Street Journal By Jared A. Favole Of DOW JONES NEWSWIRES NEW ORLEANS (Dow Jones)--A once-a-week version of the diabetes drug Byetta by Amylin Pharmaceuticals Inc. (AMLN) was better at c...


Trending Topics

Close